renal anemia
Conditions
Interventions
Intervention type:
Name of intervention:
Dose form / Japanese Medical Device Nomenclature:
Route of administration / Site of application:
Dose per administration:
Dosing frequency / Frequency of use:
Sponsors
shogo kimura
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients three times a week hemodialysis have received more than one year. hemodialysis patients with no change over the past one month in the esa administration. Patients with hb concentration of the past three months has remained at 12g/dL fc is less than the normal value 40.0 Patients over 20 years old Patient obtained a consent with respect to the present.
Exclusion criteria
Exclusion criteria: Patients with hypersensitivity to levocarnitine (Erukaruchin R) Patients with obvious factors that influence the Hb concentration, such as moderate or severe infectious diseases, malignant tumor, hemorrhage, collagen disease, chronic liver disease, low-nutrition, and blood disease Less than serum ferritin value is 100ng / mL MCV is less than 90fL, more 105fL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RBC, Hb,% retic, retic, TC, FC, AC value, AC in the blood cells, the length of the carbon chain | — |
Secondary
| Measure | Time frame |
|---|---|
| Of hypersensitivity to levocarnitine (Erukaruchin R) patients, of obvious factors that influence the Hb concentration, such as moderate or severe infectious diseases, malignant tumor, hemorrhage, collagen disease, chronic liver disease, low-nutrition, and blood disease some patients, serum ferritin value is less than 100ng / mL, MCV is less than 90fL, more 105fL | — |
Countries
Japan
Contacts
Public Contactshogo kimura
ryogoku ekimae dialysis clinic
Outcome results
None listed